This trade activity should not be overlooked: Esperion Therapeutics Inc (ESPR)

With 1.96 million shares changed hands, the volume of the stock remained lighter than its average volume of 5.68 million shares. The 52-week range on ESPR shows that it touched its highest point at $3.94 and its lowest point at $1.58 during that stretch. It currently has a 1-year price target of $6.76. Beta for the stock currently stands at 1.04.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ESPR was down-trending over the past week, with a drop of -2.67%, but this was down by -17.27% over a month. Three-month performance dropped to -15.35% while six-month performance rose 2.25%. The stock lost -32.09% in the past year, while it has lost -17.27% so far this year. A look at the trailing 12-month EPS for ESPR yields -0.66 with Next year EPS estimates of -0.06. For the next quarter, that number is -0.13. This implies an EPS growth rate of 84.40% for this year and 80.23% for next year.

Float and Shares Shorts:

At present, 195.44 million ESPR shares are outstanding with a float of 195.08 million shares on hand for trading.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ESPR since 8 analysts follow the stock currently. There are 6 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.27292 being high and -$0.33842 being low. For ESPR, this leads to a yearly average estimate of -$0.31659. Based on analyst estimates, the high estimate for the next quarter is -$0.22 and the low estimate is -$0.22. The average estimate for the next quarter is thus -$0.22.